Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

European real-world data indicate that front-line treatment with caplacizumab is associated with improved clinical outcomes compared with delayed caplacizumab treatment. The objective of the study was to describe the characteristics, treatment patterns, and outcomes in hospitalized patients with an...

Full description

Bibliographic Details
Main Authors: Alix Arnaud MS, Samantha Schilsky PhD, MPH, Jackie Lucia BS, Marta Maia MS, Fernando Laredo MS, Ana Paula Marques MD, Hikaru Okada MD, PhD, Andrew W. Roberts PharmD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2024-03-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296241241525

Internet

https://doi.org/10.1177/10760296241241525

Similar Items